莱茵生物(002166) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥376,805,771.89, representing an increase of 11.77% compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2023 was ¥4,704,255.81, a decrease of 88.93% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥346,243.78, a decline of 100.82% compared to the previous year[4]. - The basic earnings per share for Q3 2023 was ¥0.01, down 85.71% from the same period last year[5]. - Total operating revenue for Q3 2023 was ¥888,977,405.17, a decrease of 9.15% compared to ¥978,883,646.66 in Q3 2022[31]. - Net profit for Q3 2023 was ¥53,121,628.32, a decline of 71.16% from ¥184,333,491.43 in Q3 2022[32]. - Total comprehensive income for the period attributable to the parent company was CNY 61,200,951.16, compared to CNY 235,041,553.64 in the previous period, representing a decrease of approximately 74%[33]. - Basic and diluted earnings per share for the current period were both CNY 0.06, down from CNY 0.30 in the previous period, indicating an 80% decline[33]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥4,502,245,102.53, an increase of 1.05% from the end of the previous year[5]. - The company's total assets as of September 30, 2023, were ¥4,502,245,102.53, slightly up from ¥4,455,475,726.26 at the beginning of the year[28]. - Current assets totaled ¥2,384,550,325.24, down 10% from ¥2,648,118,143.52 at the start of the year[27]. - Total liabilities amounted to ¥1,375,691,101.18, an increase from ¥1,342,235,374.15 in the previous period[29]. - The company's cash and cash equivalents decreased to ¥261,026,898.60 from ¥551,740,866.95 at the beginning of the year[26]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥109,862,688.55, a decrease of 17.52% compared to the previous year[4]. - Net cash flow from operating activities was CNY 109,862,688.55, a decrease of about 17.5% from CNY 133,200,628.82 in the previous period[36]. - Cash inflow from operating activities totaled CNY 1,032,920,684.97, slightly down from CNY 1,059,595,375.87, reflecting a decrease of approximately 2.5%[36]. - Cash outflow from operating activities was CNY 923,057,996.42, compared to CNY 926,394,747.05 in the previous period, showing a marginal decrease[36]. - The net cash flow from investing activities for the first nine months of 2023 was -365,269,140.15 RMB, a decrease of 36.75% compared to -267,109,083.21 RMB in the same period of 2022, primarily due to increased expenditures on the construction of the stevia extraction factory and the natural health product research institute[15]. - Net cash flow from investing activities was CNY -365,269,140.15, worsening from CNY -267,109,083.21 in the previous period[37]. - Cash flow from financing activities resulted in a net outflow of CNY -28,709,062.66, contrasting sharply with a net inflow of CNY 1,037,369,130.36 in the previous period[37]. - The ending balance of cash and cash equivalents was CNY 237,817,401.84, down from CNY 968,033,105.23 at the end of the previous period, indicating a decrease of approximately 75%[37]. Investments and Expenditures - The company reported a significant decrease in cash and cash equivalents, down 52.69% to ¥261,026,898.60 due to project expenditures and dividend payments[10]. - The company’s long-term equity investments increased by 192.41% to ¥5,411,095.78, reflecting additional investments in associated companies during the reporting period[10]. - As of September 30, 2023, the company had invested a total of 335,777,372.74 RMB in fundraising projects, with 311,466,795.34 RMB allocated to the stevia extraction factory construction[23]. - The company has a remaining balance of 637,293,280.97 RMB in unutilized fundraising, with 475,000,000 RMB temporarily supplementing working capital[23]. - The net cash flow from financing activities was -28,709,062.66 RMB, a significant decline of 102.77% from 1,037,369,130.36 RMB in the previous year, mainly due to the non-public offering proceeds received in the same period last year[15]. Business Operations - The company's plant extraction business generated revenue of 88,897.74 million RMB in the first three quarters of 2023, down 9.18% year-on-year, while the natural sweetener segment saw a revenue decline of 15.15% to 52,270.97 million RMB[19]. - The company experienced a 121.16% increase in tax and surcharges, totaling ¥6,539,380.75, primarily due to property tax payments by overseas subsidiaries[12]. - The company’s financial expenses increased by 191.52% to ¥14,906,440.09, attributed to higher interest expenses and reduced foreign exchange gains[13]. - The contract with Firmenich for natural sweeteners has a total amount of 34,500,000 USD, with a fulfillment progress of 74.30% as of the reporting period[21]. - The company plans to focus on expanding its market presence and enhancing R&D efforts for new products[30]. - The company adjusted its 2022 restricted stock incentive plan to better align with business growth and shareholder interests, ensuring effective long-term development[24].